Story Poster
Photo by Baylor Athletics
Baylor Basketball

Postgame Podcast & Takeaways: Baylor 94 Norfolk St 69

December 11, 2024
1,151

What I Loved

  • Rob Wright did a great job controlling the show against a team that came into the game top 100 in defensive turnover percentage.  Wright was really efficient offensively (ridiculous 174 offensive rating).  He scored 16 points on 10 shots which is great, but the most important stat as a point guard is 13 assists and only one turnover.  
  • VJ Edgecombe’s energy makes this team go.  He makes some mistakes and gets out of position at times.  But he does so many things that affect winning by getting deflections, rebounds, assists, blocks, steals and he can score in bunches as well.  Stat line was a thing of beauty- 16 points on 11 shots, 9 rebounds, 4 assists, 3 steals and only one turnover.  
  • Liked the energy and efforts from Ojianwuna and Omier in the paint.  You know Omier is going to bring it every night.  My favorite play is the Rob Wright slip pass to Omier at the foul line and Omier driving for a lay-up.  Good luck defending that.  Seems like it results in a bucket about 80% of the time.  Josh did a good job finishing today and not turning it over.  I feel like his defense is taking a step as well.  
  • Overall, I liked the energy on defense.  Forcing 20 turnovers is a good number.  The Bears had a whopping 16 steals.  You also love the 25 assists and only 8 turnovers on the Bears end of the court.  
  • Free throw defense was solid, holding an 81% free throw shooting team to 62%.  

Concerns

  • Norfolk State shot 49% from the field and 56% from 3.  It’s amazing that we beat them by 25 given those stats.  We need to do a better job contesting shots (without fouling).  
  • I want to see more consistency from the free throw line.  We only missed 6 today but to be the type of team we want to be, you would like to see that number get closer to 80% as a team.  
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.